FAST NEWS: InnoCare Pharma Slumps after Flagship Drug Included on China’s National List
The latest: InnoCare Pharma Ltd. (9969.HK) said late Friday that its Bruton’s tyrosine kinase inhibitor Orelabrutinib, used to treat lymphoma and autoimmune diseases, has been included on the National Reimbursement…
RELATED ARTICLES
-
FAST NEWS: InnoCare’s loss narrows on higher lymphoma drug sales
9969.HK
-
FAST NEWS: InnoCare inches closer to profitability on strong sales gains
9969.HK
-
Debt pressures cast cloud over Fosun Pharma results
2196.HK 600196.SHG
-
FAST NEWS: Four Sihuan affiliate products included in China’s national health plan
0460.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
IFlytek hives off health unit to fund AI medical drive
002230.SHE
- Margins ring alarm bells as 160 Health readies IPO
Discover hidden China stock gems in our weekly newsletter